Drug patents …
… from Kazakhstan to Kalamazoo

Find generic entry opportunities

Deep knowledge on
small-molecule drugs and
the global patents
covering them

Manage your pharmacy inventory

Project your formulary budget

Anticipate generic drug launch

BioPharmaceutical Business Intelligence

Analyze global market entry opportunities
Obtain formulation and manufacturing information
Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020705

« Back to Dashboard

NDA 020705 describes RESCRIPTOR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the RESCRIPTOR profile page.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Two suppliers are listed for this compound. Additional details are available on the delavirdine mesylate profile page.

Summary for NDA: 020705

Tradename:	1
Applicant:	1
Ingredient:	1
Patents:	1
Therapeutic Class:	Antivirals
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020705

Ingredient-type	Non-Nucleoside Analog
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors

Suppliers and Packaging for NDA: 020705

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705	NDA	KAISER FOUNDATION HOSPITALS	0179-0096	0179-0096-70	30 TABLET in 1 BOX, UNIT-DOSE (0179-0096-70)
RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705	NDA	ViiV Healthcare Company	49702-209	49702-209-24	360 TABLET in 1 BOTTLE (49702-209-24)

Summary for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	100MG
Approval Date:	Apr 4, 1997	TE:		RLD:	Yes

Summary for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	200MG
Approval Date:	Jul 14, 1999	TE:		RLD:	Yes
Patent:	► Subscribe	Patent Expiration:	Jun 7, 2019	Product Flag?		Substance Flag?		Delist Request?

Expired Orange Book Patents for NDA: 020705

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	► Subscribe	► Subscribe
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	► Subscribe	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.